Development PipelineSGN-STNV

An antibody–drug conjugate being investigated in Sialyl-Thomsen-nouveau (STn)-expressing advanced solid tumors

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

SGNSTNV-001: Advanced solid tumors

  • Phase 1

  • Phase 2

  • Phase 3

Program Resources

High-level synopsis of SGN-STNV and ongoing clinical trials

Detailed information about SGN-STNV clinical trials